Announce Joint

• Pharmaceutical giants Eli Lilly and Pfizer announced a strategic research collaboration focusing on oncology and immunology, with combined commitments totaling $4.8 billion over five years to accelerate drug development and clinical trial timelines. • The partnership will leverage Eli Lilly's metabolic disease expertise and Pfizer's vaccine platform capabilities to pursue combination therapies for hard-to-treat cancers, with initial clinical trials expected to commence in mid-2027. • Industry analysts view the deal as emblematic of Big Pharma consolidating R&D resources amid rising drug development costs exceeding $2.6 billion per approved medication, while also signaling confidence in oncology market growth.

• Japan and South Korea formalized a expanded military cooperation agreement on Thursday, establishing joint command structures and coordinated response protocols to address escalating North Korean weapons development and missile tests. • The two nations agreed to share real-time intelligence on North Korean military activities and established a rapid-response task force designed to coordinate anti-missile defense systems within 48 hours of any provocation. • The agreement represents the strongest formal defense partnership between the two countries in over a decade and signals growing concern about North Korea's advancing intercontinental ballistic missile capabilities.